CPRX (Catalyst Pharmaceuticals, Inc.) Stock Financials & Earnings

CPRXCatalyst Pharmaceuticals, Inc.

Mkt Cap$3B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$589M

Net Income (TTM)$214M

EPS (TTM)$1.68

Free Cash Flow (TTM)$209M

Gross Margin85.2%

Op. Margin43.8%

Net Margin36.4%

FCF Margin35.4%

P/S Ratio (TTM)5.3x

P/E Ratio (TTM)14.5x

YoY Rev Growth+19.8%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$85M	$75M	$36M
Q2 23	$100M	$88M	$47M
Q3 23	$103M	$89M	-$37M
Q4 23	$111M	$95M	$42M
Q1 24	$99M	$86M	$27M
Q2 24	$123M	$107M	$54M
Q3 24	$129M	$109M	$51M
Q4 24	$142M	$120M	$63M
Q1 25	$141M	$124M	$63M
Q2 25	$147M	$117M	$66M
Q3 25	$148M	$123M	$66M
Q4 25	$153M	$139M	$62M

Revenue Breakdown

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 23	$4M	$12M	$18M	—
Q2 23	$4M	$10M	$18M	—
Q3 23	$84M	$12M	$22M	—
Q4 23	$2M	$13M	$29M	—
Q1 24	$3M	$22M	$25M	—
Q2 24	$3M	$14M	$26M	—
Q3 24	$3M	$43M	$3M	—
Q4 24	$4M	$14M	$31M	—
Q1 25	$4M	$44M	$3M	—
Q2 25	$4M	$42M	$4M	—
Q3 25	$3M	$45M	$3M	—
Q4 25	$2M	—	—	$53M

Revenue Segments

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$148M	$0	$148M
Q2 23	$179M	$0	$179M
Q3 23	$121M	$0	$121M
Q4 23	$138M	$0	$138M
Q1 24	$310M	$0	$310M
Q2 24	$376M	$0	$376M
Q3 24	$442M	$0	$442M
Q4 24	$518M	$0	$518M
Q1 25	$581M	$0	$581M
Q2 25	$653M	$0	$653M
Q3 25	$690M	$0	$690M
Q4 25	$709M	$0	$709M

Shares Outstanding

Revenue Per Employee

Revenue / Employee